Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 14 Jul 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.
- 07 Apr 2017 New trial record